ENOVIS CORP (ENOV) Stock Fundamental Analysis
NYSE:ENOV - New York Stock Exchange, Inc. - US1940141062 - Common Stock - Currency: USD
We assign a fundamental rating of 4 out of 10 to ENOV. ENOV was compared to 190 industry peers in the Health Care Equipment & Supplies industry. ENOV has a medium profitability rating, but doesn't score so well on its financial health evaluation. ENOV has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
ENOV had positive earnings in the past year.
ENOV had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: ENOV reported negative net income in multiple years.
Of the past 5 years ENOV 4 years had a positive operating cash flow.
1.2 Ratios
ENOV has a Return On Assets of -2.15%. This is in the better half of the industry: ENOV outperforms 67.55% of its industry peers.
ENOV has a better Return On Equity (-3.58%) than 69.15% of its industry peers.
Looking at the Return On Invested Capital, with a value of 0.14%, ENOV is in the better half of the industry, outperforming 65.43% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -2.15% | ||
| ROE | -3.58% | ||
| ROIC | 0.14% |
ROA(3y)-0.07%
ROA(5y)-1.35%
ROE(3y)0.06%
ROE(5y)-2.79%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With a decent Operating Margin value of 0.44%, ENOV is doing good in the industry, outperforming 65.96% of the companies in the same industry.
In the last couple of years the Operating Margin of ENOV has declined.
ENOV has a Gross Margin (56.96%) which is in line with its industry peers.
ENOV's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 0.44% | ||
| PM (TTM) | N/A | ||
| GM | 56.96% |
OM growth 3Y-44.8%
OM growth 5Y-32.38%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y11.34%
GM growth 5Y11.84%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so ENOV is destroying value.
ENOV has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, ENOV has more shares outstanding
ENOV has a worse debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of 1.29, we must say that ENOV is in the distress zone and has some risk of bankruptcy.
ENOV has a Altman-Z score (1.29) which is in line with its industry peers.
A Debt/Equity ratio of 0.40 indicates that ENOV is not too dependend on debt financing.
ENOV's Debt to Equity ratio of 0.40 is in line compared to the rest of the industry. ENOV outperforms 43.09% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.4 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.29 |
ROIC/WACC0.02
WACC8.68%
2.3 Liquidity
ENOV has a Current Ratio of 2.27. This indicates that ENOV is financially healthy and has no problem in meeting its short term obligations.
ENOV has a Current ratio (2.27) which is comparable to the rest of the industry.
A Quick Ratio of 1.12 indicates that ENOV should not have too much problems paying its short term obligations.
ENOV has a Quick ratio of 1.12. This is in the lower half of the industry: ENOV underperforms 72.34% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.27 | ||
| Quick Ratio | 1.12 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 13.30% over the past year.
Measured over the past years, ENOV shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -19.18% on average per year.
Looking at the last year, ENOV shows a very strong growth in Revenue. The Revenue has grown by 20.52%.
Measured over the past years, ENOV shows a decrease in Revenue. The Revenue has been decreasing by -4.89% on average per year.
EPS 1Y (TTM)13.3%
EPS 3Y-16.82%
EPS 5Y-19.18%
EPS Q2Q%30.36%
Revenue 1Y (TTM)20.52%
Revenue growth 3Y-17.77%
Revenue growth 5Y-4.89%
Sales Q2Q%21%
3.2 Future
Based on estimates for the next years, ENOV will show a very strong growth in Earnings Per Share. The EPS will grow by 22.12% on average per year.
ENOV is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 11.71% yearly.
EPS Next Y18.15%
EPS Next 2Y15.82%
EPS Next 3Y15.99%
EPS Next 5Y22.12%
Revenue Next Year23.86%
Revenue Next 2Y14.44%
Revenue Next 3Y11.92%
Revenue Next 5Y11.72%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 16.18, ENOV is valued correctly.
Based on the Price/Earnings ratio, ENOV is valued cheaper than 87.77% of the companies in the same industry.
ENOV's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 29.63.
With a Price/Forward Earnings ratio of 13.27, ENOV is valued correctly.
Based on the Price/Forward Earnings ratio, ENOV is valued cheaply inside the industry as 90.96% of the companies are valued more expensively.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.68, ENOV is valued a bit cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.18 | ||
| Fwd PE | 13.27 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, ENOV is valued cheaper than 86.17% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 13.8 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as ENOV's earnings are expected to grow with 15.99% in the coming years.
PEG (NY)0.89
PEG (5Y)N/A
EPS Next 2Y15.82%
EPS Next 3Y15.99%
5. Dividend
5.1 Amount
ENOV does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
42.71
-1.19 (-2.71%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners111.54%
Inst Owner Change0.17%
Ins Owners0.98%
Ins Owner Change0.04%
Market Cap2.43B
Analysts83.53
Price Target66.3 (55.23%)
Short Float %8.88%
Short Ratio5.93
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)9.42%
Min EPS beat(2)2.6%
Max EPS beat(2)16.23%
EPS beat(4)4
Avg EPS beat(4)6.21%
Min EPS beat(4)1.38%
Max EPS beat(4)16.23%
EPS beat(8)8
Avg EPS beat(8)8.12%
EPS beat(12)12
Avg EPS beat(12)8.8%
EPS beat(16)15
Avg EPS beat(16)7.32%
Revenue beat(2)0
Avg Revenue beat(2)-1.93%
Min Revenue beat(2)-2.12%
Max Revenue beat(2)-1.74%
Revenue beat(4)2
Avg Revenue beat(4)-0.81%
Min Revenue beat(4)-2.12%
Max Revenue beat(4)0.45%
Revenue beat(8)4
Avg Revenue beat(8)-0.8%
Revenue beat(12)5
Avg Revenue beat(12)-6.02%
Revenue beat(16)6
Avg Revenue beat(16)-12.33%
PT rev (1m)-1.52%
PT rev (3m)-4.41%
EPS NQ rev (1m)-0.08%
EPS NQ rev (3m)0.58%
EPS NY rev (1m)0%
EPS NY rev (3m)0.42%
Revenue NQ rev (1m)-0.34%
Revenue NQ rev (3m)-0.34%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.05%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.18 | ||
| Fwd PE | 13.27 | ||
| P/S | 1.21 | ||
| P/FCF | N/A | ||
| P/OCF | 25.95 | ||
| P/B | 0.73 | ||
| P/tB | N/A | ||
| EV/EBITDA | 13.8 |
EPS(TTM)2.64
EY6.18%
EPS(NY)3.22
Fwd EY7.54%
FCF(TTM)-1.09
FCFYN/A
OCF(TTM)1.65
OCFY3.85%
SpS35.2
BVpS58.57
TBVpS-8.08
PEG (NY)0.89
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -2.15% | ||
| ROE | -3.58% | ||
| ROCE | 0.18% | ||
| ROIC | 0.14% | ||
| ROICexc | 0.14% | ||
| ROICexgc | 0.58% | ||
| OM | 0.44% | ||
| PM (TTM) | N/A | ||
| GM | 56.96% | ||
| FCFM | N/A |
ROA(3y)-0.07%
ROA(5y)-1.35%
ROE(3y)0.06%
ROE(5y)-2.79%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y-46.9%
ROICexcg growth 5Y-17.32%
ROICexc growth 3Y-47.24%
ROICexc growth 5Y-32.21%
OM growth 3Y-44.8%
OM growth 5Y-32.38%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y11.34%
GM growth 5Y11.84%
F-Score2
Asset Turnover0.36
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.4 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 4.81 | ||
| Cap/Depr | 58.22% | ||
| Cap/Sales | 7.77% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 33.93% | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.27 | ||
| Quick Ratio | 1.12 | ||
| Altman-Z | 1.29 |
F-Score2
WACC8.68%
ROIC/WACC0.02
Cap/Depr(3y)47.98%
Cap/Depr(5y)48.74%
Cap/Sales(3y)7.07%
Cap/Sales(5y)5.74%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)13.3%
EPS 3Y-16.82%
EPS 5Y-19.18%
EPS Q2Q%30.36%
EPS Next Y18.15%
EPS Next 2Y15.82%
EPS Next 3Y15.99%
EPS Next 5Y22.12%
Revenue 1Y (TTM)20.52%
Revenue growth 3Y-17.77%
Revenue growth 5Y-4.89%
Sales Q2Q%21%
Revenue Next Year23.86%
Revenue Next 2Y14.44%
Revenue Next 3Y11.92%
Revenue Next 5Y11.72%
EBIT growth 1Y-40.91%
EBIT growth 3Y-54.61%
EBIT growth 5Y-35.68%
EBIT Next Year105.88%
EBIT Next 3Y35.94%
EBIT Next 5Y27.26%
FCF growth 1Y-169.07%
FCF growth 3Y-59.14%
FCF growth 5Y-39.44%
OCF growth 1Y22.64%
OCF growth 3Y-23.54%
OCF growth 5Y-9.82%